SÜLFONAMİDOBENZOTİYAZOL TÜREVİ hGSTP1-1 İNHİBİTÖRLERİNİN TASARIMI

Year 2020, Volume: 44 Issue: 3, 388 - 396, 30.09.2020

Kayhan Bolelli

https://doi.org/10.33483/jfpau.748521

Abstract

Amaç: Glutatyon Transferazlar (GST), ekzojen ve endojen kaynaklı, elektrofilik ve hidrofobik bileşiklerin GSH ile konjugasyonunu katalizleyen Faz-II detoksifikasyon enzim ailesidir. GST izozimlerinden en önemlisi olan hGSTP1-1’in çok farklı insan kaynaklı tümörde fazla miktarda salgılandığı ve kanser tedavisinde çoklu ilaç direnç (MDR) gelişimine sebep olduğu bilinmektedir. Tüm bu nedenlerden dolayı son zamanlarda hGSTP1-1 enzimi kanser tedavisi için bir hedef haline gelmiştir. Bu çalışmanın amacı yeni hGSTP1-1 inhibitörleri tasarlamaktır. 

Gereç ve Yöntem: 5F-203 bileşiğinden hareketle, önilaç şeklinde etki gösterebileceği düşünülen bir seri sülfonamidobenzotiyazol türevi bileşik tasarlanmıştır. Bu bileşiklerin hGSTP1-1 enzimi ile etkileşimlerini incelemek üzere Schrodinger Maestro programı kullanılarak moleküler doking çalışmaları yapılmıştır.

Sonuç ve Tartışma: Bu çalışmada 5F-203 bileşiğinden hareketle, önilaç şeklinde etki gösterebileceği düşünülen bileşiklerin, GST enzimi aracılığıyla metabolizasyonu sırasında gerçekleşen hidrolizle 5F-203 ve türevi bileşikler açığa çıkararak antitümör özellik gösterebilecekleri düşünülmüştür. Tasarlanan bileşiklerin hGSTP1-1 enzimi ile etkileşimlerini incelemek üzere yapılan doking çalışmalarına göre bileşiklerin tamamının hGSTP1-1 enzimi ile kuvvetli etkileşimlerinin olduğu gözlenmiştir. Bileşiklerin tamamının hGSTP1-1 enzim inhibisyonu için önemli olan Arg13 ve Tyr7 ile hidrojen bağı ve Tyr108 ile pi-pi etkileşimleri gösterdiği belirlenmiştir. Bir sonraki basamak olarak bu bileşiklerin sentezi gerçekleştirilecek ve hGSTP1-1 enzimi üzerindeki etkileri deneysel olarak test edilecektir. Böylece yapı-etki ilişkileri tanımlanarak daha etkili yeni bileşiklerin tasarlanması ve böylece direnç mekanizması inhibe edilerek antikanser ilaçların etkinliğinin artırılması söz konusu olabilecektir.

Keywords

antikanser, doking, hGSTP1-1, ilaç direnci, sülfonamidobenzotiyazol

Supporting Institution

Ankara Üniversitesi Bilimsel Araştırma Projeleri

Project Number

18H0237002

Thanks

Bu çalışma, Ankara Üniversitesi Bilimsel Araştırma Projeleri (Proje No: 18H0237002) tarafından desteklenmiştir.

DESIGN OF SULFONAMIDOBENZOTHIAZOLE DERIVATIVES AS hGSTP1-1 INHIBITORS

Abstract

Objective: The glutathione transferases (GSTs) are a family of widely distributed Phase II detoxification enzymes that catalyse the conjugation of exogenius and endogenius electrophilic and hydrophobic compounds. GSTP1-1 is frequently overexpressed in rat and human tumours. It is suggested that overexpression of hGSTP1-1 by human tumor cells may play a role in multi drug resistance (MDR) to cancer chemotherapy. Hence, hGSTP1-1 can be a promising target for cancer treatment. The aim of this study is to design new hGSTP1-1 inhibitors.

Material and Method: a series of sulfonamidobenzothiazole derivatives which are thought to act as prodrug have been designed based on the 5F-203 compound. To examine the interactions of these compounds with the hGSTP1-1 enzyme, molecular docking studies were carried out, by using the Schrodinger Maestro Software.

Result and Discussion: In this study, considering the compound 5F-203, it is thought that the compounds thought to be effective in the form of prodrugs may exhibit antitumor properties by releasing 5F-203 and its derivative compounds by hydrolysis during metabolism by GST enzyme. It has been observed that all of the compounds have strong interactions with the enzyme hGSTP1-1, according to the doking studies conducted to examine the interactions of the designed compounds with the enzyme hGSTP1-1. It was determined that all of the compounds showed hydrogen bonding with Arg13 and Tyr7, which are important for hGSTP1-1 enzyme inhibition, and pi-pi interactions with Tyr108. As a next step, the synthesis of these compounds will be carried out and their effects on the enzyme hGSTP1-1 will be tested experimentally. Thus, by defining structure-activity relationships, it can be possible to design more effective new compounds and increase the effectiveness of anticancer drugs by inhibiting the resistance mechanism.

Keywords

anticancer, docking, drug resistance, hGSTP1-1, sulfonamidobenzothiazole

Project Number

18H0237002

References

• 1. Townsend, D.M., Tew, K.D. (2003). The role of glutathione S-transferase in anti-cancer drug resistance. Oncogene, 22(47), 7369-7375.
• 2. Adler, V., Yin, Z., Fuchs, S.Y., Benerza, M., Rosario, L., Tew, K.D., Pincus, M.R., Sardana, M., Henderson, C.J., Wolf, C.R., Davis, R.J., Ronai, Z. (1999). Regulation of JNK signaling by GSTp. EMBO J, 18(5), 1321-1334.
• 3. Armstrong, R.N. (1987). Enzyme-catalyzed Detoxication Reactions: Mechanisms and Stereochemistry. Crit. Rev. Biochem. Mol. Biol., 22(1), 39-88.
• 4. Bolelli, K., Musdal, Y., Aki-Yalcin, E., Mannervik, B., Yalcin, I. (2017). Synthesis and activity mechanism of some novel 2-substituted benzothiazoles as hGSTP1-1 enzyme inhibitors. SAR QSAR Environ. Res., 28(11), 927-940.
• 5. Jakobsson, P.J., Morgenstern, R., Mancini, J., Ford-Hutchinson, A., Persson, B. (1999). Common structural features of MAPEG-a widespread super family of associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci., 8, 689-692.
• 6. Mathew, N., Kalyanasundaram, M., Balaraman, K. (2006). Glutathione S-transferase (GST) inhibitors. Exp. Opin. Ther. Pat., 16(4), 431-444.
• 7. Armstrong, R.N. (1997). Structure, Catalytic Mechanism, and Evolution of the Glutathione Transferases. Chem. Res. Toxiol., 10(1), 2-18.
• 8. Raghunathan, S., Chandross, R.J., Kretsinger, R.H., Allison, T.J., Penington C.J., Rule, G.S. (1994). Crystal structure of human class mu glutathione transferase GSTM2-2. Effects of lattice packing on conformational heterogeneity. J. Mol. Biol., 238(5), 815-832.
• 9. Reinemer, P., Dirr, H.W., Ladenstein, R., Schaffer, J., Gallay, O., Huber, R. (1991). The three-dimensional structure of class pi glutathione S-transferase in complex with glutathione sulfonate at 2.3 A resolution. EMBO J., 10(8), 1997-2005.
• 10. Sinning, I., Kleywegt, G.J., Cowan, S.W., Reinemer, P., Dirr, H.W., Huber, R., Gilliland, G.L., Armstrong, R.N., Ji, X., Board, P.G. (1993) Structure determination and refinement of human alpha class glutathione transferase A1-1, and a comparison with the Mu and Pi class enzymes. J. Mol. Biol., 232(1), 192-212.
• 11. Oakley, A. (2011). Glutathione transferases: a structural perspective. Drug Metab. Rev., 43(2), 138-151.
• 12. Tew, K.D., Bomber, A.M., Hoffman, S.J. (1988). Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res., 48(13), 3622-3625.
• 13. Tozkoparan, B., Aytaç, S.P. (2007). Kanser kemoterapisinde terapötik hedef olarak glutatyon S-transferazlar. Hacettepe Üniv. Ecz. Fak. Derg., 27(2), 139-164.
• 14. Wang, Z., Jin, L., Wegrzyn, G., Wegrzyn, A. (2009). A novel method for screening the glutathione transferase inhibitors. BMC Biochemistry, 10(6), 1-11.
• 15. Chen, C., Wu, C., LU, X., Yan, Z., Gao, J., Zhao, H., Li, S. (2013). Coniferyl Ferulate, a Strong Inhibitor of Glutathione S-Transferase Isolated from Radix Angelicae sinensis, Reverses Multidrug Resistance and Downregulates P-Glycoprotein. Hindawi Publ Corp, 639083, 1-10.
• 16. Oakley, A.J., Lo Bello, M., Mazzetti, A.P., Federici, G., Parker, M.W. (1997). The glutathione conjugate of etharynic acid can bind to human pi class glutathione transferase P1-1 in two different modes. FEBS Letters, 419, 32-36.
• 17. Zhao, Z., Koeplinger, K.A., Peterson, T., Conradi, R.A., Burton, P.S., Suarato, A., Heinrikson, R.L., Tomasselli, A.G. (2009). Mechanism, Structure-Activity Studies, and Potential Applications of Glutathione S-Transferase-catalyzed Cleavage of Sulfonamides. Drug Metab Dispos, 27(9), 992-998.
• 18. Trapani, V., Patel, V., Leong, C.-O., Ciolino, H.P., Yeh, G.C., Hose, C., Trepel, J.B., Stevens, M.F.G., Sausville, E.A., Loaiza-Perez, A.I. (2003). DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. British Journal of Cancer, 88, 599–605.
• 19. Ertan-Bolelli, T., Musdal, Y., Bolelli, K., Yılmaz, S., Aksoy, Y., Yıldız, I., Akı-Yalcın, E., Yalcın, I. (2014). Synthesis, Biological Evaluation of 2-Substituted-5-(4-nitrophenylsulfonamido) benzoxazoles as Human GST P1-1 Inhibitors and Description of the Binding Site Features, ChemMedChem, 9(5-SI), 984-992.
• 20. Chikhi, A., Bensegueni, A. (2008). Comparative study of the efficiency of three protein-ligand docking programs. J. Proteomics Bioinf., 1(3), 161-165.
• 21. Schneider, G., Böhm H. J. (2002). Virtual screening and fast automated docking methods. Drug Discovery Today, 7(1), 64-70.
• 22. Toledo-Sherman, L. M., Chen, D. (2002). High-throughput virtual screening for drug discovery in parallel. Curr. Opin. Drug Discovery Dev., 5(3), 414–421.
• 23. Lengauer, T., Rarey, M. (1996). Computational methods for biomolecular docking, Curr. Opin. Struct. Biol., 6(3), 402–406.
• 24. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., Shenkin, P. S. (2004). Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem., 47(7), 1739-1749.
• 25. Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., Banks, J. L. (2004). Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening, J. Med. Chem., 47(7), 1750-1759.